Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML3228

Sigma-Aldrich

Rimiducid

≥90% (HPLC)

Sinónimos:

(S,2S,2′S)-((1R,1′R)-1,1′-(3,3′-(2,2′-(Ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy)bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl)) bis(1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate), 1,1′-{Ethylenebis[azanediyl(2-oxoethane-2,1-diyl)oxy-3,1-phenylene]}bis[(1R)-3(3,4-dimethoxyphenyl)propyl]bis{(2S)-1-[(2S)-2-(3,4,5trimethoxyphenyl)butanoyl]piperidine-2-carboxylate}, 2,2′-[1,2-Ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene[(1R)-3-(3,4-dimethoxyphenyl)propylidene]]] bis[(2S)-1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-2-piperidinecarboxylate], AP 1903, AP-1903, AP1903

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C78H98N4O20
Número de CAS:
195514-63-7
Peso molecular:
1411.63
Número MDL:
MFCD25976784
Código UNSPSC:
12352200
NACRES:
NA.77

Nivel de calidad

100

Ensayo

≥90% (HPLC)

Formulario

powder

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear (Warmed)

temp. de almacenamiento

-10 to -25°C

cadena SMILES

N2([C@@H](CCCC2)C(=O)O[C@H](CCc8cc(c(cc8)OC)OC)c3cc(ccc3)OCC(=O)NCCNC(=O)COc4cc(ccc4)[C@H](OC(=O)[C@H]6N(CCCC6)C(=O)[C@@H](CC)c7cc(c(c(c7)OC)OC)OC)CCc5cc(c(cc5)OC)OC)C(=O)[C@@H](CC)c1cc(c(c(c1)OC)OC)OC

Clave InChI

GQLCLPLEEOUJQC-ZTQDTCGGSA-N

Acciones bioquímicas o fisiológicas

High-affinity FKBP12 F36V mutant cross-linker for Chemical Induction of Dimerization (CID) of Chimeric Antigen Receptor (CAR) in vitro and in vivo.
Rimiducid (AP1903) is a homodimeric FKBP12 Phe36Val (F36V-FKBP, FKBP-F36V) mutant-selective cross-linker composed of two high-affinity ligands, each with 713-fold selectivity over endogenous FKBP (Kd = 94 pM/F36V- vs 67 nM/Wt-FKBP using 4′-AF-labeled rimiducid). Rimiducid activates signaling events via Chemical Induction of Dimerization (CID) by cross-linking FKBP12-F36 fusions (Chimeric Antigen Receptor or CAR) expressed in cells in cultures (apoptosis induction EC50 = 0.1 nM; HT1080 expressing FKBP(F36V)-Fas intracellular domain) and in animals in vivo (EC50 = 0.4 mg/kg i.v. in a murine model of conditional cell ablation).

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000389464
0000389465
0000389465
0000389464
0000233341

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Carolina Berger et al.
Blood, 103(4), 1261-1269 (2003-10-18)
Conditional suicide genes derived from pathogens have been developed to confer drug sensitivity and enhance safety of cell therapy, but this approach is limited by immune responses to the transgene product. We examined a strategy to regulate survival of transferred
Kenneth A Matreyek et al.
Nucleic acids research, 48(1), e1-e1 (2019-10-16)
Multiplex genetic assays can simultaneously test thousands of genetic variants for a property of interest. However, limitations of existing multiplex assay methods in cultured mammalian cells hinder the breadth, speed and scale of these experiments. Here, we describe a series
D C Thomis et al.
Blood, 97(5), 1249-1257 (2001-02-27)
Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation. One strategy to treat GVHD is to equip donor T cells with a conditional suicide mechanism that can be triggered when GVHD occurs. The herpes simplex virus thymidine
Dongpeng Jiang et al.
Leukemia, 34(3), 821-830 (2019-10-19)
CD19-redirected CAR-T immunotherapy has emerged as a promising strategy for treatment of B cell lymphoma, however, many patients often relapsed due to antigen loss. Therefore, it is urgently needed to explore other suitable antigens targeted by CAR-T cells to cure
Xiaoou Zhou et al.
Blood, 125(26), 4103-4113 (2015-05-16)
To test the feasibility of a single T-cell manipulation to eliminate alloreactivity while sparing antiviral and antitumor T cells, we infused 12 haploidentical hematopoietic stem cell transplant patients with increasing numbers of alloreplete haploidentical T cells expressing the inducible caspase
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico